ORKA Stock Summary and Trading Ideas (Oruka Therapeutics | NASDAQ:ORKA)

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics trades on the NASDAQ stock market under the symbol ORKA.

As of February 9, 2026, ORKA stock price climbed to $33.26 with 162,488 million shares trading.

ORKA has a beta of 1.65, meaning it tends to be more sensitive to market movements. ORKA has a correlation of 0.13 to the broad based SPY ETF.

ORKA has a market cap of $1.61 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ORKA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

ORKA has outperformed the market in the last year with a return of +154.3%, while the SPY ETF gained +15.7%. In the last 3 month period, ORKA beat the market returning +17.6%, while SPY returned +3.8%. However, in the most recent 2 weeks ORKA has underperformed the stock market by returning -3.3%, while SPY returned +0.7%.

ORKA support price is $31.60 and resistance is $34.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORKA shares will trade within this expected range on the day.